Fact CheckerSign in

NCT07047508Not yet recruiting

Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction

A Non-interventional Study of the Effectiveness and Safety Outcomes in Patients With Heart Failure and Preserved Ejection Fraction (HFpEF) Initiating Jardiance in China: A Sub-study of the Post-marketing Study of Jardiance Among Patients With Heart Failure in China

Source: ClinicalTrials.gov · Last updated 16 Sept 2026

Brief summary (registry, in English)

The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
3000 (estimated)
First submitted
24 Jun 2025
Start date
31 Jan 2028
Primary completion date
31 Dec 2028
Lead sponsor
Boehringer Ingelheim
NCT number
NCT07047508

What you commit to

  • Study type: Observational
  • Planned participants: 3000
  • From 31 Jan 2028 to the primary completion date, 31 Dec 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Lab values

  • -Patients treated with any other sodium-glucose cotransporter-2 inhibitors (SGLT2i) on the index date or during the look-back period

Who the study is looking for

  • At least 18 years of age
  • At least 6 months of data prior to the index date
  • Left ventricular ejection fraction (LVEF) \> 40 %
  • N-terminal Pro-B-type natriuretic peptide (NT-proBNP) \> 125 pg/mL or brain natriuretic peptide (BNP) ≥ 35 pg/mL
  • At least 1 diagnosis of Heart failure with preserved ejection fraction (HFpEF) or Heart failure with mid-range ejection fraction (HFmrEF) or chronic heart failure (CHF) at baseline during the look-back period (on or prior to the index date)
  • New users of Jardiance® (initiating Jardiance® on or after March 1st, 2023, and without any record of Jardiance® prescription during the look-back period)
  • Body Mass Index (BMI) \<45 kg/m2

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.